MET activation promotes the cancer stem cell phenotype [5, 6] and HGF/MET signaling plays a crucial role in the development of resistance to classical cytotoxic therapy and targeted therapy, such as EGFR and BRAF inhibitors [7–9]. This evidence concerns the gene HGF and cancer.